Sujiet Puthenveetil

Sujiet Puthenveetil is a Director at AstraZeneca, where he leads a dynamic, multidisciplinary team focused on advancing targeted delivery technologies in Oncology and other therapeutic areas. He manages highly productive teams of Protein engineers, Analytical chemists, Radiochemists, Synthetic chemists, and Bioconjugation scientists, centered on driving the development of Antibody-Drug Conjugates (ADC), Antibody-Oligo Conjugates (AOC), and Radioligand Therapies (RLT) into clinical trials, with notable projects such as AZD9829 and FPI-2068.

Sujiet is an experienced senior leader who also co-leads a team of Biological Engineering colleagues responsible for delivering pre-clinical assets to Oncology Targeted Delivery (OTD). His responsibilities encompass shaping scientific strategies, guiding project leads, overseeing long-term FTE and budget planning, conducting due diligence, and managing pipeline milestones.

Prior to joining AstraZeneca, Sujiet served as a Principal Scientist at AbbVie, where his team successfully delivered multiple ADCs for auto-immune indications, such as ABBV-154. With over 14 years of industrial experience, he commenced his career at Pfizer, focused on and delivering novel site-specific technologies for ADCs, including PF-06804103. Sujiet holds a Ph.D. in Chemical Biology from the University of Utah and completed his postdoctoral research in Protein Engineering at MIT.